Turing Pharmaceuticals CEO Martin Shkreli still hasn’t lowered the price of AIDS medication

Turing Pharmaceuticals CEO Martin Shkreli still hasn’t lowered the price of AIDS medication

THE chief executive of US-based pharmaceuticals company Turing Pharmaceuticals, Martin Shkreli, made headlines across the globe last month when his company increased the price of the prescription drug Daraprim which people living with AIDS use, from $13.50 USD per pill to $750 USD per pill.

[showads ad=MREC]After public backlash, Shkreli made a public statement saying he would lower the cost of the drug to make it more affordable.

Daraprim is a prescription drug used by doctors who treat patients with AIDS and cancer to combat a parasite that attacks people with a weakened immune system.

Speaking to ABC News last month, Shkreli said: “We’ve agreed to lower the price of Daraprim to a point that is more affordable and is able to allow the company to make a profit, but a very small profit.”

According to reports from lgbtqnation, it has been two weeks since he assured the world he would lower the price of his drug, but the price has’t changed.

The drug, which has been around 62 years, is available in Australia as a generic for $25 per box of 50.

[showads ad=FOOT]

You May Also Like

Comments are closed.